CSBR

Champions Oncology, Inc. (CSBR) Business Model Analysis (2026)

Invetso Score: 6.2/10 — Balanced · Last Updated: 2026-09-01

Monthly Update
Overall Score6.46.2
Change-0.2

Revenue Model

Score: 7.5 (Strong)

Champions Oncology’s revenue model is anchored by high-margin, recurring oncology services with strong client retention and multi-year contracts, supporting predictable cash flows and moderate growth.

Cost Structure

Score:

Champions Oncology maintains a lean, asset-light cost structure with disciplined capex and ongoing R&D investment, but profitability remains fragile and margin expansion has not yet fully taken hold.

Scalability

Score:

Champions Oncology’s scalable, asset-light model supports growth, but operating leverage remains modest and broader market reach is still developing.

Diversification

Score:

Champions Oncology’s business is concentrated by service line, client type, and geography, resulting in moderate diversification and some exposure to sector and client risk.

Defensibility

Score:

Champions Oncology’s defensibility is supported by proprietary models and client relationships, but competitive pressures and limited scale constrain its moat relative to larger CROs.

Overall Score

Score:

Champions Oncology demonstrates a solid, high-margin revenue model and an asset-light structure, but profitability remains fragile with only marginal EBITDA positivity and negative net income. Limited diversification and competitive pressures continue to temper the business model, leaving execution on growth and margin expansion as the key value driver.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Champions Oncology, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →